273 related articles for article (PubMed ID: 32726650)
1. Emerging insights on drug delivery by fatty acid mediated synthesis of lipophilic prodrugs as novel nanomedicines.
Fattahi N; Shahbazi MA; Maleki A; Hamidi M; Ramazani A; Santos HA
J Control Release; 2020 Oct; 326():556-598. PubMed ID: 32726650
[TBL] [Abstract][Full Text] [Related]
2. Lipid Drug Conjugates for Improved Therapeutic Benefits.
Shrivastava P; Gautam L; Jain A; Vishwakarma N; Vyas S; Vyas SP
Curr Pharm Des; 2020; 26(27):3187-3202. PubMed ID: 32160838
[TBL] [Abstract][Full Text] [Related]
3. Supramolecular nanomedicines through rational design of self-assembling prodrugs.
Wang H; Monroe M; Leslie F; Flexner C; Cui H
Trends Pharmacol Sci; 2022 Jun; 43(6):510-521. PubMed ID: 35459589
[TBL] [Abstract][Full Text] [Related]
4. Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery.
Pan D; Pham CT; Weilbaecher KN; Tomasson MH; Wickline SA; Lanza GM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016; 8(1):85-106. PubMed ID: 26296541
[TBL] [Abstract][Full Text] [Related]
5. Lipidic prodrug approach for improved oral drug delivery and therapy.
Markovic M; Ben-Shabat S; Keinan S; Aponick A; Zimmermann EM; Dahan A
Med Res Rev; 2019 Mar; 39(2):579-607. PubMed ID: 30320896
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy agent-unsaturated fatty acid prodrugs and prodrug-nanoplatforms for cancer chemotherapy.
Sun B; Luo C; Cui W; Sun J; He Z
J Control Release; 2017 Oct; 264():145-159. PubMed ID: 28844757
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances on Cellulose-Based Nano-Drug Delivery Systems: Design of Prodrugs and Nanoparticles.
Dai L; Si C
Curr Med Chem; 2019; 26(14):2410-2429. PubMed ID: 28699504
[TBL] [Abstract][Full Text] [Related]
8. Albumin-binding prodrugs via reversible iminoboronate forming nanoparticles for cancer drug delivery.
Hao L; Zhou Q; Piao Y; Zhou Z; Tang J; Shen Y
J Control Release; 2021 Feb; 330():362-371. PubMed ID: 33359484
[TBL] [Abstract][Full Text] [Related]
9. Lipid-Drug Conjugate for Enhancing Drug Delivery.
Irby D; Du C; Li F
Mol Pharm; 2017 May; 14(5):1325-1338. PubMed ID: 28080053
[TBL] [Abstract][Full Text] [Related]
10. Dimeric prodrug-based nanomedicines for cancer therapy.
Li S; Shan X; Wang Y; Chen Q; Sun J; He Z; Sun B; Luo C
J Control Release; 2020 Oct; 326():510-522. PubMed ID: 32721523
[TBL] [Abstract][Full Text] [Related]
11. Fabrication of Cellulose-Nanocrystal-Based Folate Targeted Nanomedicine via Layer-by-Layer Assembly with Lysosomal pH-Controlled Drug Release into the Nucleus.
Li N; Zhang H; Xiao Y; Huang Y; Xu M; You D; Lu W; Yu J
Biomacromolecules; 2019 Feb; 20(2):937-948. PubMed ID: 30621397
[TBL] [Abstract][Full Text] [Related]
12. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo.
Wang W; Xi M; Duan X; Wang Y; Kong F
Int J Nanomedicine; 2015; 10():3737-50. PubMed ID: 26045664
[TBL] [Abstract][Full Text] [Related]
13. Taxanes prodrug-based nanomedicines for cancer therapy.
Sun L; Zhao P; Chen M; Leng J; Luan Y; Du B; Yang J; Yang Y; Rong R
J Control Release; 2022 Aug; 348():672-691. PubMed ID: 35691501
[TBL] [Abstract][Full Text] [Related]
14. Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency.
Lin MH; Hung CF; Hsu CY; Lin ZC; Fang JY
Future Med Chem; 2019 Aug; 11(16):2131-2150. PubMed ID: 31538520
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of cyclic graft polymeric prodrugs with heterogeneous grafts of hydrophilic OEG and reducibly conjugated CPT for controlled release.
Meng C; Cao Y; Sun L; Liu Y; Kang G; Ma W; Peng J; Deng K; Ma L; Wei H
Biomater Sci; 2020 Jul; 8(15):4206-4215. PubMed ID: 32555884
[TBL] [Abstract][Full Text] [Related]
16. Enhancing Oral Performance of Paclitaxel Lipid-Mimic Prodrug via Modulating Type of Fatty Acids.
Miao YF; Ye Q; Zhang MY; Gao L; Wang XY; Zhong WX; Wang ZX; He ZG; Tian CT; Sun J
Adv Healthc Mater; 2023 Jul; 12(19):e2203118. PubMed ID: 36929289
[TBL] [Abstract][Full Text] [Related]
17. Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy.
Mandal A; Patel M; Sheng Y; Mitra AK
Curr Drug Targets; 2016; 17(15):1773-1798. PubMed ID: 26648076
[TBL] [Abstract][Full Text] [Related]
18. pH-Responsive Self-Assemblies from the Designed Folic Acid-Modified Peptide Drug for Dual-Targeting Delivery.
Wang D; Fan Z; Zhang X; Li H; Sun Y; Cao M; Wei G; Wang J
Langmuir; 2021 Jan; 37(1):339-347. PubMed ID: 33356306
[TBL] [Abstract][Full Text] [Related]
19. Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38.
Bala V; Rao S; Boyd BJ; Prestidge CA
J Control Release; 2013 Nov; 172(1):48-61. PubMed ID: 23928356
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticles as delivery carriers for anticancer prodrugs.
Fang JY; Al-Suwayeh SA
Expert Opin Drug Deliv; 2012 Jun; 9(6):657-69. PubMed ID: 22507134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
